Skip to main content
Figure 8 | BMC Cancer

Figure 8

From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Figure 8

3-year follow-up analysis of Panagen clinical trial. Percentage of relapse events and deaths of patients relatively to the total number of patients. Data for patients from the base II (FAC and AC regimen) are presented. Each group of bars is labeled to show the percentage of patients having stage II, III or IV cancers.

Back to article page